Bicara Therapeutics (BCAX) Non Operating Income (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Non Operating Income of $4.1 million for Q1 2026, down 18.57% year-over-year from $5.0 million in Q1 2025, and up 7.76% quarter-over-quarter from $3.8 million in Q4 2025.
Bicara Therapeutics (BCAX) Non Operating Income (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 18.57% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $16.9 million (up 1.27% YoY), while the FY2025 annual figure was $17.9 million, up 22.56% from the prior year.
- Non Operating Income for Q1 2026 stood at $4.1 million, up from $3.8 million in the prior quarter.
- The five-year high for Non Operating Income was $5.9 million in Q4 2024, with the low at -$13.3 million in Q3 2023.
- The 4-year median for Non Operating Income is $3.8 million (2025), against an average of $2.2 million.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 368.53% in 2024, then slumped 35.41% in 2025.
- Bicara Therapeutics' Non Operating Income stood at $1.3 million in 2023, then surged by 368.53% to $5.9 million in 2024, then plunged by 35.41% to $3.8 million in 2025, then climbed by 7.76% to $4.1 million in 2026.
- Business Quant data shows BCAX's Non Operating Income at $4.1 million in Q1 2026, $3.8 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 4.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.58 Mn |
| Mar 31, 2026 | 4.08 Mn |
| Dec 31, 2025 | 3.79 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 4.68 Mn |
| Mar 31, 2025 | 5.01 Mn |
| Dec 31, 2024 | 5.87 Mn |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | -13.32 Mn |